Camille Montersino Selected Research

Therapeutics

1/2023	From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia.
1/2022	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Camille Montersino Research Topics

Disease

3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2017
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2023
1	Fanconi Anemia (Fanconi's Anemia) 01/2023
1	Neoplasms (Cancer) 01/2023
1	Oncogene Addiction 01/2022
1	Leukemia 12/2017

Drug/Important Bio-Agent (IBA)

1	Galectin 1 (LGALS1)IBA 04/2023
1	Pre-B Cell ReceptorsIBA 04/2023
1	NucleotidesIBA 01/2023
1	Melphalan (Alkeran)FDA LinkGeneric 01/2023
1	Deoxycytidine KinaseIBA 01/2023
1	DeoxyribonucleotidesIBA 01/2023
1	DNA (Deoxyribonucleic Acid)IBA 01/2023
1	EnzymesIBA 01/2023
1	trametinibIBA 01/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022
1	src-Family KinasesIBA 12/2017

Therapy/Procedure

2	Therapeutics 01/2023 - 01/2022
1	Drug Therapy (Chemotherapy) 01/2017